June 3, 2024Open Access

Table 2 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Key Points

Key points are not available for this paper at this time.

Abstract

Breakdown of case and control classification in the test data (N = 25,369) using 10-year risks from the Tyrer-Cuzick model with and without PRSBC, with a fixed proportion (6.47%) of women considered at “moderate risk”.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Collister et al. (Mon,) studied this question.

synapsesocial.com/papers/68e6672fb6db6435875f3a1f https://doi.org/https://doi.org/10.1158/1055-9965.25957044

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 2 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank2024
2Table 3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank2024
3Table 3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank2024
4Table 1 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank2024
5Table 1 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank2024

Bookmark

View Full Paper